Zhonghong Boyuan Secures Nearly RMB 1 Billion in Series A Funding to Advance Human Disease Animal Model Innovation

VCBeat (WeChat: vcbeat) has learned that Jiangxi Zhonghong Boyuan Biotechnology Co., Ltd. (hereinafter referred to as “Zhonghong Boyuan” or the “Company”) recently announced it had secured nearly RMB 100 million in its Series A financing round, led by an industrial investor and participated by Tan Zhen New Healthcare Fund, with Tan Zhen Capital serving as the exclusive financial advisor. The funds will be used to enhance production capacity for orders, expand business scale, and increase R&D investment. The lead industrial investor holds a strong positive outlook on the niche sector of laboratory animal models and decided to invest in Zhonghong Boyuan, aligning with the consensus among prominent domestic investors.

Investors believe that Zhonghong Boyuan is a leading enterprise in China for the development of human disease animal models, specializing in providing an integrated service platform featuring surgical models for drug development and life sciences research. The company’s core competitiveness lies in its independently constructed library of human disease models, which covers a wide variety of animal species and disease areas. It has currently accumulated 206 methods for preparing disease animal models and is expected to establish a comprehensive human disease animal model library covering all types of surgical disease models within five years.

Yue Bingfei, a researcher at the National Institutes for Food and Drug Control (NIFDC) and a member of the National Committee of the Chinese People's Political Consultative Conference (CPPCC), stated that, according to incomplete statistics, over 80% of Nobel Prize-winning achievements in Physiology or Medicine rely on animal model resources or technological innovations, and 100% of new drug development depends on animal models. Animal model resources are strategic assets for future competition in biomedical science and technology, as well as the “litmus test” for original drug research and development.

In this round of industrial capital investment, Zhonghong Boyuan was selected not only for its technology but also, more importantly, for its management team. The founder of Zhonghong Boyuan is a physician by training who possesses a deep understanding of the pain points in R&D within the fields of medicine and life sciences. With multiple successful entrepreneurial ventures and extensive management experience, he is committed to contributing to the advancement of medical research. He has built a learning-oriented team with strong complementary skills.

Zhonghong Boyuan boasts a high-caliber talent pool, with over 200 full-time employees, including a technical team of more than 120 members. Among them, there are 8 PhD holders and nearly 50 Master’s degree holders.

According to statistics, the domestic market size for animal models of human diseases is nearly RMB 10 billion, while the market size for new drug R&D CROs exceeds RMB 100 billion. The industry is growing at an annual rate of 15–20%, and the company has maintained a business growth rate of 50% in recent years.

Following the completion of its Series A financing, Jiangxi Zhonghong Boyuan will accelerate its IPO process and is poised to become the first listed company in Jiangxi Province specializing in biomedical technical services.